<DOC>
	<DOCNO>NCT02835924</DOCNO>
	<brief_summary>The purpose study assess safety tolerability different dose-escalation approach regorafenib mCRC patient .</brief_summary>
	<brief_title>Study Comparing Different Dose Approaches Induction Treatment Regorafenib MCRC</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent ( IC ) obtain study specific procedure . Subjects must able understand willing sign write informed consent . 2 . Male female subject 18 year age . 3 . Life expectancy least 3 month . 4 . Histological cytological documentation adenocarcinoma colon rectum . All histological type exclude . 5 . Measurable metastatic stage IV disease least 1 measurable metastatic lesion follow RECIST criterion v 1.1 . 6 . Subjects metastatic colorectal cancer ( Stage IV ) . 7 . Progression within 3 month follow last administration approve standard therapy must include fluoropyrimidine , oxaliplatin , irinotecan , antiVEGF antiEGFR ( RAS WT ) 8 . Subjects treat oxaliplatin adjuvant setting progress within 6 month completion adjuvant therapy 9 . Subjects progress 6 month completion oxaliplatin contain adjuvant treatment must retreat oxaliplatinbased therapy eligible . Subjects withdrawn standard treatment due unacceptable toxicity warrant discontinuation treatment preclude retreatment agent prior progression disease also allow study 10 . ECOG Performance Status 0 1 ( within 14 day prior initiation study treatment ) 11 . Adequate bone marrow , liver renal function assess follow laboratory requirement : Total bilirubin =1.5 x upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = 2.5 x ULN ( 5 x ULN subject liver involvement cancer ) . Alkaline phosphatase limit = 2.5 x ULN ( 5 x ULN subject liver and/or bone involvement cancer ) . Lipase = 1.5 x ULN . Serum creatinine 1.5 x ULN = 30 mL/min calculate use CockcroftGault equation . Platelet count &gt; 100000/mm3 , hemoglobin &gt; 9 g/dL , absolute neutrophil count ( ANC ) &gt; 1500/mm3 . International normalized ratio ( INR ) / Partial thromboplastin time ( PTT ) 1.5 x ULN . ( Subjects therapeutically treat agent warfarin heparin allow participate provide prior evidence underlie abnormality coagulation parameter exist . Close monitoring least weekly evaluation perform INR/PTT stable base measurement predose define local standard . Blood transfusion meet inclusion criterion allow . 12 . Women childbearing potential men must agree use adequate contraception enter program least 8 week last study drug administration . The investigator designate associate request advise subject achieve adequate birth control . Adequate contraception define study medically recommend method ( combination method ) per standard care . Women childbearing potential must blood urine pregnancy test perform maximum 7 day start study treatment , negative result must document start study treatment . 1 . Prior treatment regorafenib . 2 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study drug 3 . Pregnant breastfeeding subject : 4 . Congestive heart failure = New York Heart Association ( NYHA ) class 2 . 5 . Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . 6 . Myocardial infarction le 6 month start study drug . 7 . Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) . 8 . Uncontrolled hypertension . ( Systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) . 9 . Arterial venous thromboembolism within 6 month prior randomization . 10 . Pleural effusion ascites cause respiratory compromise ( CTCAE Grade 2 dyspnea ) . 11 . Ongoing infection &gt; Grade 2 CTCAE v. 4.0 . 12 . Known history human immunodeficiency virus ( HIV ) infection . 13 . Known history active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy . 14 . Subjects seizure disorder require medication . 15 . History organ allograft . 16 . Subjects evidence history bleed diathesis , irrespective severity . 17 . Any hemorrhage bleeding event = CTCAE Grade 3 within 4 week prior start study medication . 18 . Nonhealing wound , ulcer , bone fracture . 19 . Renal failure require hemoor peritoneal dialysis . 20 . Dehydration CTCAE v. 4.0 Grade = 1 . 21 . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result . 22 . Known hypersensitivity study drug , study drug class , excipients formulation . 23 . Any illness medical condition unstable could jeopardize safety subject his/her compliance study . 24 . Interstitial lung disease ongoing sign symptom 25 . Persistent proteinuria CTCAE Grade 3 ( &gt; 3.5g/24 hour ) . 26 . Subjects unable swallow oral medication . 27 . Any malabsorption condition . 28 . Unresolved toxicity high CTCAE ( v. 4.0 ) &gt; Grade 1 attribute prior therapy/procedure exclude alopecia , hypothyroidism oxaliplatin induced neurotoxicity &gt; Grade 2 . 29 . Subjects treat strong CYP3A4 inhibitor inducer ( refer appendix 8 section 6.3.8 . Prohibited concomitant medication ) . 30 . Subjects receive GCSF within 3 week prior sign ICF 31 . Concomitant participation participation within last 30 day another clinical trial 32 . Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , hormonal therapy trial within 4 week ( within 6 week mitomycin C ) start receive study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>regorafenib</keyword>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>